Related Experiment Video
Updated: Jul 17, 2026
10:29
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
PDGFR-beta expression in small cell lung cancer patients
Eric T Shinohara1, Adriana Gonzalez, Pierre P Massion
1Department of Medicine, Abington Memorial Hospital, Abington, PA, USA.
International Journal of Radiation Oncology, Biology, Physics
|January 24, 2007
Summary
Platelet-derived growth factor receptor beta (PDGFR-beta) is common in small cell lung cancer (SCLC). However, PDGFR-beta expression levels do not predict overall survival in SCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Platelet-derived growth factor (PDGF) and its receptor PDGFR-beta show prognostic value in various human cancers.
- Previous research suggests PDGFR is a potential therapeutic target in non-small-cell lung cancer.
- This study investigates PDGFR-beta expression and its prognostic significance in small cell lung cancer (SCLC).
Purpose of the Study:
- To determine the expression levels of PDGFR-beta in SCLC tumors.
- To evaluate the prognostic value of PDGFR-beta expression for overall survival in SCLC patients.
Main Methods:
- Immunohistochemical staining was performed on 53 SCLC tissue samples.
- Tumor samples were stained for PDGFR-beta using specific antibodies.
- Patients were categorized into low and high PDGFR-beta staining groups based on intensity.
Main Results:
- High PDGFR-beta staining was observed in 20 patients, while 29 showed low staining.
- Only 4 patients had no detectable PDGFR-beta staining.
- No significant difference in 5-year overall survival was found between low and high PDGFR-beta expression groups (p = 0.538).
Conclusions:
- The majority of SCLC patients express PDGFR-beta at low or high levels.
- PDGFR-beta expression is not a statistically significant predictor of 5-year overall survival in SCLC.
